The Regulator's Eye — Reading Your Own Materials from the Inspection Standpoint

When a review team reads a piece of promotional material, a second set of eyes is needed — one asking: "If regulators saw this, what would they question?" Since 2016, Japan's Ministry of Health, Labour and Welfare has collected real-world data on pharmaceutical sales information activities through monitors placed at medical institutions, feeding findings into administrative guidance. Understanding that perspective from the inside does more than keep problem materials from slipping through. It puts the ability to explain why something is problematic — back into the hands of the people doing the reviewing.

So what / So why — The core of this perspective

Regulators look at the effect of a communication, not its appearance. The question is not whether the product name appears on a slide, but what happens to prescribing behavior after a clinician receives the information. The FY2025 (Reiwa 7) report makes this explicit: activities under surveillance include "acts where evidence is hard to document (such as verbal explanations), and acts that, while not clearly false or exaggerated, are considered likely to encourage inappropriate use." In other words, even when a document contains no obvious defects, the structure of the explanation as a whole is subject to scrutiny.

So what — what gets flagged — can be stated plainly: when a gap between evidence and a claim distorts prescribing decisions, that gap aligns with what the Pharmaceutical and Medical Device Act and the guidelines prohibit. Font size on a figure, or excessive adjectives, are not the issue. What is at issue is the structure of an explanation designed so that clinicians walk away thinking "that drug seems safer" or "the competing product has problems" — when the data does not actually say that.

So why is this serious? Two reasons. First, when individual violations accumulate, regulators classify the case as "high in severity," which triggers administrative guidance coordinated with prefectural authorities — and the company name appears as a case study in the published report. Second, the FY2025 report records that some cases "suggested deliberate effort by the sales organization." The moment organizational involvement becomes visible, the question shifts from one individual's lapse to the company's compliance structure as a whole.

Inside the perspective — What / Where / Why / How

What — What regulators look for in a material

Five focal points. First, the logical relationship between evidence and claims — does the cited data actually support the claim? If only a non-inferiority trial exists, is the material claiming superiority? Second, how safety information is handled — is efficacy prominent while risks and adverse events appear small, late, or hedged? Third, references to competing products — is language suggesting a competitor's weaknesses present without comparative data to back it up? Fourth, off-label or unapproved information — has anything outside the approved indication, dosage, or use crept in? Fifth, consistency with verbal explanation — even when the document looks clean, has anyone thought through how the MR will actually present it?

Where — Which media and settings regulators focus on

The large majority of cases collected by the monitoring program involve in-person MR visits and online meetings. Mass email distribution has appeared as a case type in recent reports. Sales activities using press releases are also under sustained attention as activities that "may constitute promotional information-provision." The closer a medium sits to the boundary between "advertising" and "explanatory activity," the sharper the regulatory focus becomes.

Why — The reasoning behind the scrutiny

Patients cannot evaluate prescription drug information directly. It reaches them only through physicians and pharmacists. When the information supplied to those specialists is distorted, the final safeguard for patient protection stops working. The phrase repeated throughout the monitoring reports — "creating an environment in which medicines are used appropriately" — is a summary of that logic.

How — The decision process

It is staged. Reports from monitor institutions are organized by the secretariat, then reviewed case by case in a case-review committee composed of academics, MHLW staff, and the lead monitor coordinators, who assess each one as appropriate or not. MHLW makes the final determination. Cases of high severity are referred to prefectural authorities for administrative guidance; cases where improvement is desirable are handled through coordination with relevant MHLW divisions. The FY2025 report sets out an explicit "severity determination flowchart" — a signal that regulators are deliberately distinguishing between degrees of seriousness. Cases where an MR apologized on the spot and the encounter ended there are also flagged with a note that "intentional provision of inappropriate information is suspected," meaning the sincerity of the corrective response is itself part of the evaluation.

Stepping into the role — What the standpoint actually feels like

Imagine sitting on the case-review committee, holding a report just received from a monitor institution. A clinician has documented that an MR, during an online meeting, repeatedly named a competing product out loud while drawing comparisons — even though the slides showed only generic ingredient names.

The first thing to establish is whether the MR misspoke by accident, or chose a method: keep product names off the slides, use them only verbally. The FY2021 (Reiwa 3) antibacterial case does exactly this. The report records: "While the slide materials used only ingredient names without specifying product names, the verbal explanation repeatedly named competing products by their brand names and compared them to the company's own product." Keeping the document clean while naming competitors only in speech is a structural choice. That is how a committee member reads it.

The next question is less about whether the MR had bad intentions and more about what happened to the physician's prescribing after that explanation. The purpose is not to judge motive. It is to protect the quality of information that reaches patients. On that basis, unintentional lapses are still subject to a correction request. At the same time, committee members hold a second concern: that companies become so cautious that information provision dries up. The FY2025 report includes clinicians' own observations — that more companies have grown overly hesitant to share information, and that MRs are providing little beyond what is already printed in the product information summary. Regulators explicitly regard the failure of clinicians to receive needed information in a timely way as its own problem.

Both sides of that tension — no tolerance for violation, no tolerance for paralysis — frame how a case gets read. That is the practical reality of the regulatory perspective.

Past cases as a mirror — Rereading old lapses through this lens

When past cases are read through the regulatory lens, the criteria used to judge severity become visible.

Case 1: Unverified "crisis" anecdote with no established causation (FY2025)

During an in-person visit to a medical institution, an MR relayed oral information that "two patients in the prefecture experienced adverse events after taking Competitor B's product and required surgery," then stated that "this must be regarded as an abnormal situation" and urged the institution to switch prescriptions to Company A's product (a metabolic drug, in-person visit).

Read through the regulatory lens, three problems overlap. First, an adverse event with no confirmed causal link was delivered wrapped in the emotionally loaded phrase "abnormal situation." Second, that information was connected directly to pressure for a prescription switch. Third, only unfavorable information about Competitor B was introduced — no adverse event information about Product A was presented at all. The case was simultaneously classified under two categories: defamation and disparagement of a competing product, and "other" acts of arbitrary inducement without scientific basis — both of which the guidelines prohibit. The full record of cases from FY2019 through FY2025, including this one, is documented in Case Dissection No. 7: Defamation and Disparagement of Competing Products.

Case 2: Sleep-related adverse event comparison — concealing the difference in denominators (FY2025)

At a new drug presentation, an MR stated that sleep-related adverse events occurred in "over ten percent" of patients on Competitor B's product versus "2.4%" on Company A's Product A (a peripheral nervous system drug, in-person visit). When a clinician later checked the interview forms, it turned out that the figure for Product B was the overall adverse event incidence rate, while the 2.4% for Product A was the incidence of somnolence alone. The actual incidence of somnolence for Product B was below 1% — lower than Product A's.

Read through the regulatory lens, the report's phrase "explanation likely to cause factual misunderstanding" hits the center of the problem. Both numbers may have been accurately quoted, but placing figures that use different denominators side by side manipulates the impression. This is a case type that is flagged as one where "intentional provision of inappropriate information is suspected." From a materials review standpoint, this case teaches that any numerical comparison requires verifying what the denominator is and exactly what is being placed next to what.

PEST — Reading the external environment

Political (regulation)

The monitoring program launched in FY2016 (Heisei 28). In FY2024 (Reiwa 6), the program was renamed from "monitoring project" to "investigation project." That is not a cosmetic change — it reflects a shift in the regulator's posture from surveillance toward fact-gathering and environmental improvement. Around the same time, in February 2024, the guidelines Q&A (Part 4) was issued, providing specific guidance on how comparative information about competing products may be shared appropriately. The framework grows more detailed each year, narrowing the room for "I didn't know" as an explanation.

Economic

Wider adoption of biosimilars and generics is a central plank of government healthcare cost containment. Promotional communication that works against that adoption — "biosimilars are not equivalent" or "generics don't cover all the same indications" — places individual company interests in direct conflict with public health policy. The reports also note that violations tend to cluster in highly competitive therapeutic areas, an acknowledgment that market pressure raises the risk of lapses.

Social

Clinicians have raised concerns about excessive hesitancy in information provision. The fact that regulators documented this publicly and stated that "sincere responses to information requested by clinicians are expected" signals that the purpose of the program is to raise the quality of medical information, not to enforce restrictions for their own sake. A separate "general reporting system" for non-monitor institutions has been in place since FY2019, meaning the broader medical community functions as an additional channel of information to the regulator.

Technological

The COVID-19 period normalized online meetings and web seminars, and violation cases expanded from in-person settings to online ones. Mass email distribution appeared in the FY2024 report; the FY2025 report added sales activities using press releases to its list of areas under observation. As the number of channels grows, so does the scope of what is subject to review. Reviewers need to treat printed materials, digital content, verbal explanations, and email distribution as all falling under the same guidelines — because they do.